Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of JNJ-26366821 in Healthy Volunteers
NCT03990519Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JNJ-26366821 in Thrombocytopenia (3 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of Participants with Adverse Events (AE) as a Measure of Safety and Tolerability. Started Jun 2019; status: completed.
02
Drugs
JNJ-26366821
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT03990519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03990519.